Mackenzie Financial Corp Lowers stake in Henry Schein (HSIC)

Henry Schein (HSIC) : Mackenzie Financial Corp reduced its stake in Henry Schein by 19.03% during the most recent quarter end. The investment management company now holds a total of 1,169,430 shares of Henry Schein which is valued at $201.1 Million after selling 274,919 shares in Henry Schein , the firm said in a disclosure report filed with the SEC on May 12, 2016.Henry Schein makes up approximately 1.85% of Mackenzie Financial Corp’s portfolio.

Other Hedge Funds, Including , Bbva Compass Bancshares Inc reduced its stake in HSIC by selling 1,906 shares or 9.89% in the most recent quarter. The Hedge Fund company now holds 17,375 shares of HSIC which is valued at $3 Million. Henry Schein makes up approx 0.22% of Bbva Compass Bancshares Inc’s portfolio.Commonwealth Equity Services Inc boosted its stake in HSIC in the latest quarter, The investment management firm added 678 additional shares and now holds a total of 5,119 shares of Henry Schein which is valued at $863,575. Henry Schein makes up approx 0.01% of Commonwealth Equity Services Inc’s portfolio.

Henry Schein closed down -0.14 points or -0.08% at $170.75 with 4,72,095 shares getting traded on Friday. Post opening the session at $171.03, the shares hit an intraday low of $169.645 and an intraday high of $172 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Henry Schein reported $1.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 3, 2016. Analyst had a consensus of $1.39. The company had revenue of $2712.96 million for the quarter, compared to analysts expectations of $2667.28 million. The company’s revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.28 EPS.

Many Wall Street Analysts have commented on Henry Schein. Company shares were Reiterated by Barrington Research on May 4, 2016 to “Outperform”, Firm has raised the Price Target to $ 188 from a previous price target of $182 .Henry Schein was Initiated by Credit Suisse to “Neutral” on Mar 16, 2016. Barrington Research Upgraded Henry Schein on Mar 1, 2016 to ” Outperform”, Price Target of the shares are set at $182.

Henry Schein Inc. provides health care products and services to office-based dental animal health and medical practitioners. The Company operates its business through two segments: health care distribution and technology and value-added services. The health care distribution segment distributes consumable products laboratory products equipment repair services branded and generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products and vitamins among others. The Company’s global technology and value-added services segment provides software technology and other value-added services to health care practitioners. Its offerings include practice management software systems for dental and medical practitioners and animal health clinics. Its value-added practice solutions include financial services on a non-recourse basis e-services practice technology network and hardware services as well as continuing education services for practitioners.

Leave a Reply

Henry Schein - Is it time to Sell?

Top Brokerage Firms are advising their investors on Henry Schein. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.